Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear cell renal cell carcinoma (ccRCC) This is the second ...

Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC). This is an ASCO ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In a recent update from AstraZeneca, the ...

Biomarker-driven radiation therapy dose reduction after transoral robotic surgery for the treatment of HPV-positive oropharyngeal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Arcus Biosciences has announced a clinical trial partnership with AstraZeneca to assess the combination of casdatifan (AB521) and volrustomig in patients with clear cell renal cell carcinoma (ccRCC).

(RTTNews) - Arcus Biosciences, Inc. (RCUS), Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment ...

AstraZeneca, home of cancer blockbusters like Tagrisso and Daiichi Sankyo-partnered Enhertu, wants to elevate its cancer pipeline and is sharing a peek at data from three bispecific antibody ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a Phase II ...

This trial is looking at volrustomig (MEDI5752) for head and neck cancer that has spread into the surrounding tissue and cannot be removed by surgery. Cancer that has spread into the surrounding ...

This trial is looking at having a new drug called volrustomig (MEDI5752) on its own for liver cancer. It is also looking at volrustomig in combination with bevacizumab or lenvatinib. It is open to ...

The total bispecific antibodies in oncology market size in the leading markets (the US, EU4, UK, and Japan) is expected to surge significantly by 2040. The report provides the total potential number ...

HAYWARD, Calif., October 02, 2024--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...